cGVHD

14 registered clinical trials studyying cGVHD — 9 currently recruiting.

Status	Trial	Sponsor	Phase
Not Yet Recruiting	IL6-receptor Inhibitor Iwith Belumosudil for the Treatment of Belumosudil-refractory cGVHD NCT07484113	Stanford University	Phase 1
Not Yet Recruiting	Gecacitinib in the Treatment of Steroid-Refractory/Dependent Chronic Graf Versus Host Disease (cGVHD). NCT07476872	Institute of Hematology & Blood Diseases Hospital, China	Phase 1 / Phase 2
Recruiting	A Clinical Study Evaluating the Safety and Efficacy of GT729 Universal Cell Injection in the Treatment of Refr NCT07253259	Grit Biotechnology	EARLY_Phase 1
Recruiting	BPC2001 for the Prevention of Acute Graft-Versus-Host Disease Following Haploidentical Stem Cell Transplantati NCT07246031	BioPhoenix Co., Ltd.	Phase 2
Recruiting	Treatment of Refractory cGVHD by Donor-derived Treg Cell Injection Combined With Recombinant Human Interleukin NCT06920199	Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine	EARLY_Phase 1
Recruiting	Axatilimab in Combination With Extracorporeal Photopheresis (ECP) in Chronic Graft-versus-Host Disease NCT06663722	University of Miami	Phase 2
Active Not Recruiting	Tele-Palliative Care Intervention for Patients With Chronic Graft-Versus-Host Disease NCT06458127	Massachusetts General Hospital	N/A
Not Yet Recruiting	Efficacy and Safety of Anti-CD25 rhMAb in the Treatment of Steroid-Refractory cGVHD NCT06364319	Peking University People's Hospital	Phase 4
Unknown	Safety and Efficacy of Iguratimod in the Treatment of Chronic GVHD NCT06244628	Xuzhou Medical University	Phase 3
Recruiting	Observational Study for Patients at Risk for Chronic Graft-Versus-Host Disease NCT05919511	Incyte Corporation	—
Enrolling By Invitation	A Phase II Study Evaluating the Efficacy and Safety of ABSK021 (Pimicotinib)) in the Treatment of cGvHD Chroni NCT06186804	Abbisko Therapeutics Co, Ltd	Phase 2
Withdrawn	Belimumab for Treatment of cGVHD Following Allo-HCT NCT05604742	xuna	Phase 1 / Phase 2
Unknown	Efficacy and Safety Study of 4-Day ATG Regimen for Prophylaxis of aGVHD in Matched Sibling Donor PBSCT NCT05214066	Chinese PLA General Hospital	Phase 2
Completed	Impact of Adnexal Involvement of the Severity and Prognosis of Chronic Graft-versus-Host Disease NCT01221766	Dana-Farber Cancer Institute	—